Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572

被引：0
|
作者：
Schiff, David [1 ]
Sarkaria, Jann [2 ]
Decker, Paul [2 ]
Buckner, Jan [2 ]
Galanis, Evanthia [2 ]
Dancey, Janet [3 ]
Giannini, Caterina [2 ]
Brown, Paul [2 ]
Wiesenfeld, Martin [4 ]
Jaeckle, Kurt [5 ]
机构：
[1] Univ Virginia, Hlth Sci Ctr, Charlottesville, VA USA
[2] Mayo Clin, Rochester, MN USA
[3] Natl Canc Inst, Bethesda, MD USA
[4] Cedar Rapids Oncol Project, Cedar Rapids, IA USA
[5] Mayo Clin, Jacksonville, FL 32224 USA
来源：
NEURO-ONCOLOGY | 2007年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：518 / 518
页数：1
相关论文
共 50 条
  • [41] NCCTG N0272: PHASE II TRIAL OF IMATINIB MESYLATE; (GLEEVEC; STI571) IN TREATMENT OF RECURRENT OLIGODENDROGLIOMA AND MIXED OLIGOASTROCYTOMA: A NORTH CENTRAL CANCER TREATMENT GROUP STUDY
    Jaeckle, Kurt A.
    Anderson, S. K.
    Kosel, Matt
    Sarkaria, Jann
    Brown, Paul
    Flynn, P. J.
    Buckner, Jann C.
    Galanis, Eva
    NEURO-ONCOLOGY, 2011, 13 : 89 - 89
  • [42] Relationship of administration of enzyme-inducing anticonvulsants (EIAC) to survival in patients with glioblastoma: A north central cancer treatment group (NCCTG) study
    Jaeckle, K
    Ballman, K
    Uhm, J
    O'Fallon, J
    Schomberg, P
    Scheithauer, B
    Giannini, C
    Flynn, P
    Buckner, J
    NEURO-ONCOLOGY, 2004, 6 (04) : 376 - 376
  • [43] Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)
    Kurt A. Jaeckle
    S. K. Anderson
    Erin L. Twohy
    Jesse G. Dixon
    Caterina Giannini
    Robert Jenkins
    Merrill J. Egorin
    Jann N. Sarkaria
    Paul D. Brown
    P. J. Flynn
    John Schwerkoske
    Jan C. Buckner
    Evanthia Galanis
    Journal of Neuro-Oncology, 2019, 143 : 573 - 581
  • [44] NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial.
    Ma, Daniel
    Galanis, Evanthia
    Schiff, David
    Wu, Wenting
    Peller, Patrick J.
    Giannini, Caterina
    Brown, Paul D.
    Uhm, Joon H.
    McGraw, Steven
    Jaeckle, Kurt A.
    Flynn, Patrick J.
    Buckner, Jan C.
    Sarkaria, Jann Nagina
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)
    Kurt A. Jaeckle
    S. K. Anderson
    Erin L. Twohy
    Jesse G. Dixon
    Caterina Giannini
    Robert Jenkins
    Merrill J. Egorin
    Jann N. Sarkaria
    Paul D. Brown
    P. J. Flynn
    John Schwerkoske
    Jan C. Buckner
    Evanthia Galanis
    Journal of Neuro-Oncology, 2019, 143 : 583 - 583
  • [46] Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials
    Jaeckle, K. A.
    Wu, W.
    Kosel, M.
    Flynn, P. J.
    Buckner, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
    Galanis, Evanthia
    Anderson, S. Keith
    Twohy, Erin
    Butowski, Nicholas A.
    Hormigo, Adilia
    Schiff, David
    Omuro, Antonio
    Jaeckle, Kurt A.
    Kumar, Shaji
    Kaufmann, Timothy J.
    Geyer, Susan
    Kumthekar, Priya U.
    Campian, Jian
    Giannini, Caterina
    Buckner, Jan C.
    Wen, Patrick Y.
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
  • [48] Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study (vol 27, pg 2052, 2009)
    Galanis, E.
    Jaeckle, K. A.
    Maurer, M. J.
    Reid, J. M.
    Ames, M. M.
    Hardwick, J. S.
    Reilly, J. F.
    Loboda, A.
    Nebozhyn, M.
    Fantin, V. R.
    Richon, V. M.
    Scheithauer, B.
    Giannini, C.
    Flynn, P. J.
    Moore, D. F., Jr.
    Zwiebel, J.
    Buckner, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3262 - 3262
  • [49] Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
    Brown, Paul D.
    Krishnan, Sunil
    Sarkaria, Jann N.
    Wu, Wenting
    Jaeckle, Kurt A.
    Uhm, Joon H.
    Geoffroy, Francois J.
    Arusell, Robert
    Kitange, Gaspar
    Jenkins, Robert B.
    Kugler, John W.
    Morton, Roscoe F.
    Rowland, Kendrith M., Jr.
    Mischel, Paul
    Yong, William H.
    Scheithauer, Bernd W.
    Schiff, David
    Giannini, Caterina
    Buckner, Jan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5603 - 5609
  • [50] Pharmacokinetic analysis of imatinib and CGP74588 in patients with recurrent anaplastic oligodendroglioma: North central cancer treatment group (NCCTG) N0272
    Jaeckle, Kurt
    Egorin, Merrill
    Anderson, S. Keith
    Wu, Wenting
    Sarkaria, Jann
    Galanis, Evanthia
    Brown, Paul
    Murgo, Anthony
    Buckner, Jan
    NEURO-ONCOLOGY, 2007, 9 (04) : 563 - 563
12345